Nektar Therapeutics Balance Sheet - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.89 $1.06 (4.86%) NKTR stock closing price Mar 22, 2017 (Closing)

The financial analysis of a company like Nektar Therapeutics involves checking the three financial statements of the company in detail, of which the balance sheet is one. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Nektar Therapeutics stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Nektar Therapeutics had a long term debt of $243.46M at the end of 2016-Q4. Nektar Therapeutics operating cash flow was $-117.02M while Nektar Therapeutics revenue stood at $37.45M. View Nektar Therapeutics quarterly results to get the balance sheet details for the latest & last 40 quarters data..

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Cash59.64M63.29M55.67M72.54M55.57M18.81M45.87M154.45M37.36M57M
Marketable Securities329.46M190.21M219.17M215.77M253.37M249M233.78M171.35M225.45M204.63M
Receivables15.68M14.24M27.77M39.67M19.94M2.96M3.68M2.88M3.6M46.07M
Inventory11.11M10.75M10.26M11.25M11.34M10.35M10.12M12.51M12.95M11.69M
Raw Materials2.06M2.38M2.63M3.05M3.23M1.77M2.39M2.4M2.2M1.72M
Work In Progress7.31M6.69M6.63M7.44M6.08M8.49M6.11M7.66M5.18M8.31M
Finished Goods1.74M1.67M1M0.75M2.02M0.08M1.61M2.44M5.56M1.65M
Notes Receivable----------
Other Current Assets10.36M4M5.42M5.59M9.81M5.21M8.78M6.09M8.81M4.7M
Nektar Therapeutics Total Current Assets
426.25M282.52M318.32M344.84M350.05M286.35M302.24M347.29M288.2M324.12M
Property Plant & Equipment176.84M---174.04M---164.17M-
Accumulated Depreciation111.24M---102.71M---93.8M-
Nektar Therapeutics Net Property Plant & Equipment
65.6M65.55M67.77M69.85M71.33M72.53M72.15M69.26M70.36M69.27M
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Intangibles76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M76.5M
Deposits & Other Assets0.52M0.51M0.5M0.68M4.17M13.86M5.76M6.15M6.55M7M
Nektar Therapeutics Total Assets
568.87M425.09M463.09M491.87M502.06M449.24M456.66M499.21M441.62M476.9M
Notes Payable----------
Accounts Payable2.82M7.11M2.32M2.34M2.36M2.27M2.83M5.02M2.7M5.42M
Current Portion Long-Term Debt-----125M----
Current Portion Capital Leases2.91M2.37M3.61M4.78M4.75M5.88M5.64M5.41M4.51M-
Accrued Expenses35.15M37.63M36.99M31.06M22.57M43.63M36.4M29.51M26.79M34.32M
Income Taxes Payable----------
Other Current Liabilities31.35M29.17M36.34M27.74M31.55M31.3M36.2M35.49M30.04M40.79M
Nektar Therapeutics Total Current Liabilities
72.22M76.3M79.28M65.94M61.24M208.09M81.07M75.44M64.04M80.54M
Mortgages----------
Deferred Taxes/Income51.89M57.08M60.13M59.58M62.42M68.94M73.96M78.41M76.91M82.9M
Convertible Debt----------
Long-Term Debt243.46M243M242.56M242.13M242.11M-125M125M125M125M
Non-Current Capital Leases2.22M2.14M2.75M3.32M1.07M1.33M2.88M4.38M4.13M5.33M
Other Long-Term Liabilities110.95M114.4M117.61M121.16M128.77M131.81M138.63M138.65M135.19M135.89M
Nektar Therapeutics Total Liabilities
480.75M492.94M502.35M492.15M495.63M410.19M421.56M421.9M405.28M429.68M
Minority Interest----------
Preferred Stock----------
Common Stock Net0.02M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M
Capital Surplus2.11B1.91B1.9B1.89B1.88B1.85B1.84B1.83B1.82B1.79B
Retained Earnings-2.02B-1.98B-1.94B-1.89B-1.87B-1.81B-1.81B-1.75B-1.79B-1.74B
Treasury Stock----------
Other Liabilities-2.36M-1.96M-2.01M-1.83M-2.17M-1.82M-1.49M-1.27M-1.56M-1.17M
Nektar Therapeutics Shareholders Equity
88.13M-67.85M-39.25M-0.27M6.42M39.05M35.09M77.3M36.33M47.21M
Nektar Therapeutics Total Liabilities & Shareholders Equity
568.87M425.09M463.09M491.87M502.06M449.24M456.66M499.21M441.62M476.9M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Balance sheet for another ticker

1:22
NKTR
Apart from balance sheet items, an investor would do well to keep track of the Nektar Therapeutics stock price by looking at Nektar Therapeutics historical stock prices. One can compare PE with industry average by looking at the Nektar Therapeutics PE ratio chart. The common balance sheet items are:
  • Assets: An asset is a resource that a corporation like Nektar Therapeutics owns and has monetary significance. NKTR assets grew from $425.09M in 2016-Q3 to $568.87M in 2016-Q4 . Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Nektar Therapeutics's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for NKTR stock stand at $480.75M.
.

Nektar Therapeutics Balance Sheet - Key Ratios

Current ratio
3.7
Asset Turnover
ratio
0.33
receivables turnover
ratio
8
PB ratio (
price to book ratio
)
-1330.8160